Genetron Health's two new research results in cancer are unveiled at the 2021 American Society for Molecular Pathology Annual Meeting (AMP 2021)

Beijing, November 16, 2021/PRNewswire/ - Recently, at the 2021 online annual meeting (AMP 2021) held by the American Society of Molecular Pathology, Genetron Health (NASDAQ: GTH) released two Seq-based -The latest research results of MRD® and FusionScan Plus products (Abstract No.

Dr.

Abstract number

Article title

1064612

Development and Validation of a Next Generation Sequencing Assay for Measurable Residual Disease Detection in B-lymphoid Malignancies

1062999

An integrated DNA and RNA Next Generation Sequencing Assay for simultaneously Detection of Gene mutations and Fusions

Seq-MRD®-B lymphoid blood tumor minimal residual disease high-throughput sequencing (NGS) kit product

After clinical treatment of hematological tumor patients, there are still very few tumor cancer cells that do not respond or are resistant to treatment.

This study included 56 cases of bone marrow aspiration fluid from patients with B lymphoid tumors, 40 cases of healthy human peripheral blood, 1 case of MM cell line RPMI8226, 1 case of B-ALL cell line NALM6 and other different sample types

The test results found that the Seq-MRD® detection kit showed high sensitivity and specificity in the detection of minimal residual disease of B lymphoid tumors, and can be used to accurately detect different levels of minimal residual disease in patients with clinical B lymphoid tumors

FusionScan plus - a low starting volume kit product for simultaneous detection of gene mutations and unknown gene fusions

Adequate detection of potentially beneficial gene fusions and drug-resistant mutations can guide clinical diagnosis and treatment more accurately, and high-throughput DNA and RNA sequencing detection at the same time is an ideal method for screening gene mutations and gene fusions

In response, Genetron Health has developed a second-generation sequencing kit FusionScan plus that uses DNA and RNA as templates to detect mutations and fusion genes, respectively

About AMP

The American Association for Molecular Pathology (AMP) was established in 1995.

Generic Health (Nasdaq: GTH) is a global cutting-edge cancer precision medicine company, focusing on cancer genomics research and application, and is committed to changing the way of cancer diagnosis and treatment relying on advanced molecular biology and big data analysis capabilities

This press release contains Genetron Health's future expectations, plans and forward-looking statements, which are subject to risks and uncertainties, which may cause actual results to differ from the expectations described in the forward-looking statements

Source: Genetron Health